BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26218634)

  • 1. Genetic subtypes of invasive bladder cancer.
    McConkey DJ; Choi W; Dinney CP
    Curr Opin Urol; 2015 Sep; 25(5):449-58. PubMed ID: 26218634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.
    McConkey DJ; Choi W; Ochoa A; Siefker-Radtke A; Czerniak B; Dinney CP
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):377-94, x-xi. PubMed ID: 25836941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
    Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
    Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    Pal SK; Agarwal N; Boorjian SA; Hahn NM; Siefker-Radtke AO; Clark PE; Plimack ER
    J Clin Oncol; 2016 Sep; 34(27):3346-8. PubMed ID: 27458279
    [No Abstract]   [Full Text] [Related]  

  • 6. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
    Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
    Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
    Choi W; Ochoa A; McConkey DJ; Aine M; Höglund M; Kim WY; Real FX; Kiltie AE; Milsom I; Dyrskjøt L; Lerner SP
    Eur Urol; 2017 Sep; 72(3):354-365. PubMed ID: 28365159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
    Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
    Choi W; Porten S; Kim S; Willis D; Plimack ER; Hoffman-Censits J; Roth B; Cheng T; Tran M; Lee IL; Melquist J; Bondaruk J; Majewski T; Zhang S; Pretzsch S; Baggerly K; Siefker-Radtke A; Czerniak B; Dinney CP; McConkey DJ
    Cancer Cell; 2014 Feb; 25(2):152-65. PubMed ID: 24525232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A precision, personalized approach to the management of bladder cancer.
    Apolo AB; Burger M
    Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
    Sjödahl G; Eriksson P; Liedberg F; Höglund M
    J Pathol; 2017 May; 242(1):113-125. PubMed ID: 28195647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer.
    Miyamoto DT; Mouw KW; Feng FY; Shipley WU; Efstathiou JA
    Lancet Oncol; 2018 Dec; 19(12):e683-e695. PubMed ID: 30507435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
    Balar AV; Milowsky MI
    Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts.
    Sjödahl G; Jackson CL; Bartlett JM; Siemens DR; Berman DM
    J Pathol; 2019 Apr; 247(5):563-573. PubMed ID: 30604486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Subtypes of Bladder Cancer.
    McConkey DJ; Choi W
    Curr Oncol Rep; 2018 Aug; 20(10):77. PubMed ID: 30128829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
    Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
    Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.